Chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy, is approved for two indications — relapsed or refractory large B-cell lymphoma and B-cell acute lymphoblastic leukemia — and is currently being investigated for more cancer types.
CAR T-cell therapy comprises T cells collected from a patient that are then engineered to recognize an antigen on targeted tumor cells. These cells are infused back into the patient, with the goal of guarding against recurrence and conferring long-term remissions.
To keep you up-to-date on the latest studies assessing CAR T-cell therapy, HemOnc Today compiled a list of updates on ongoing trials and cost-effectiveness analyses, including interviews with investigators conducting trials of CAR T-cell therapy for different cancer sites. Read More Here